Kyverna Therapeutics, Inc. Common Stock - Asset Resilience Ratio
Kyverna Therapeutics, Inc. Common Stock (KYTX) has an Asset Resilience Ratio of 79.47% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See financial agility of Kyverna Therapeutics, Inc. Common Stock to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Kyverna Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. See KYTX equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Kyverna Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see KYTX market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $204.25 Million | 79.47% |
| Total Liquid Assets | $204.25 Million | 79.47% |
Asset Resilience Insights
- Very High Liquidity: Kyverna Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 79.47% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kyverna Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Kyverna Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Kyverna Therapeutics, Inc. Common Stock (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Kyverna Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 52.81% | $155.16 Million | $293.83 Million | -9.35pp |
| 2024-12-31 | 62.16% | $189.36 Million | $304.64 Million | +31.71pp |
| 2023-12-31 | 30.45% | $22.90 Million | $75.19 Million | +10.15pp |
| 2022-12-31 | 20.30% | $13.59 Million | $66.92 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $85.49 Million | -- |
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product ca… Read more